Spear, Timothy T.
Wang, Yuan
Foley, Kendra C.
Murray, David C.
Scurti, Gina M.
Simms, Patricia E.
Garrett-Mayer, Elizabeth
Hellman, Lance M.
Baker, Brian M.
Nishimura, Michael I.
Funding for this research was provided by:
National Cancer Institute (P01 CA154779, R01 CA102280, R01 CA104947, R01 CA90873, R21 CA153789, F30 CA180731)
National Institute of General Medical Sciences (R35 GM118166)
Article History
Received: 1 February 2017
Accepted: 11 June 2017
First Online: 20 June 2017
Compliance with ethical standards
:
: The authors would like to acknowledge funding provided by the National Cancer Institute: P01 CA154779 (Nishimura), R01 CA102280 (Nishimura), R01 CA104947 (Nishimura), R01 CA90873 (Nishimura), R21 CA153789 (Nishimura), F30 CA180731 (Spear), and the National Institute of General Medical Sciences: R35 GM118166 (Baker).
: All recombinant DNA and retroviral transduction work was done under approved Loyola University Chicago or University of Notre Dame Institutional Biosafety Committee protocols. Human materials used were established tumor cell lines or derived from apheresis products purchased from commercial sources. Therefore, these studies are not considered Human Subjects Research and did not require Institutional Review Board approval.
: The authors declare that they have no conflict of interest.